Copenhagen, Denmark / Chicago, IL – November 17, 2026 – In a highly anticipated presentation at the American Heart Association (AHA) Scientific Sessions 2026, pharmaceutical giant Novo Nordisk today revealed the comprehensive baseline characteristics of participants enrolled in its pivotal Phase III ARTEMIS trial. The data, presented to a packed auditorium of cardiologists, endocrinologists, and clinical researchers, offers an unprecedented glimpse into the trial’s design and the high-risk patient population being studied for Novo Nordisk’s investigational multi-agonist, NV-345. This unveiling marks a critical juncture in the quest for novel therapies targeting the intertwined epidemics of type 2 diabetes, obesity, and cardiovascular disease, setting the stage for what many analysts predict could be a transformative shift in clinical practice.
n
The ARTEMIS (A Randomized Trial Evaluating Metabolic and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Established Cardiovascular Disease) trial is evaluating the long-term cardiovascular safety and efficacy of NV-345, a novel GLP-1/GIP/Glucagon receptor tri-agonist, in a global cohort of over 18,000 patients. The baseline data confirms the inclusion of a complex, high-risk population, underscoring the significant unmet medical need that NV-345 aims to address. Industry observers and healthcare providers alike are keenly awaiting the trial’s primary outcome results, expected in late 2028, which could reshape treatment paradigms for millions worldwide.
n
Main Facts: ARTEMIS Baseline Data Illuminates Patient Profile
n
Novo Nordisk’s presentation at AHA 2026 focused on the demographic and clinical characteristics of the vast patient cohort participating in the ARTEMIS trial. The data confirms the trial’s robust design and its commitment to evaluating NV-345 in a real-world, high-risk population representative of those suffering from advanced type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD).
n
Key takeaways from the baseline data include:
n
- n
- Diverse Global Cohort: The ARTEMIS trial has successfully enrolled 18,500 patients across 40 countries, reflecting a broad geographical and ethnic diversity. This global reach enhances the generalizability of future findings.
- High Cardiovascular Risk: The average age of participants is 65.2 years, with 72% having a history of a major adverse cardiovascular event (MACE), including myocardial infarction, stroke, or unstable angina requiring hospitalization. This criterion ensures the trial directly addresses the population most vulnerable to cardiovascular complications.
- Advanced Type 2 Diabetes: The mean HbA1c at baseline was 8.3%, indicating suboptimal glycemic control despite existing standard-of-care treatments in a significant portion of the cohort. The average duration of T2D was 14.7 years.
- Significant Comorbidities: Beyond T2D and ASCVD, a high prevalence of other comorbidities was noted:n
- n
- Hypertension: 91%
- Dyslipidemia: 85%
- Obesity (BMI ≥30 kg/m²): 78% (mean BMI 34.1 kg/m²)
- Chronic Kidney Disease (eGFR <60 mL/min/1.73m²): 45%
n
n
n
n
- Extensive Polypharmacy: Patients were on an average of 6.8 concomitant medications at baseline, highlighting the complexity of managing this patient population and the need for therapies that can integrate safely and effectively. Common concomitant medications included antiplatelet agents, statins, ACE inhibitors/ARBs, beta-blockers, and various glucose-lowering drugs (metformin, SGLT2 inhibitors, DPP-4 inhibitors, insulin).
n
n
n
n
n
n
The detailed baseline characteristics provide a strong foundation for the ongoing trial, confirming that the ARTEMIS study is powered to detect clinically meaningful differences in cardiovascular outcomes. The comprehensive nature of the data underscores Novo Nordisk’s commitment to rigorous clinical development and transparent reporting.
n
Chronology: A Path to Promising Multi-Agonist Therapy
n
The journey of NV-345, the investigational drug at the heart of the ARTEMIS trial, has been marked by a systematic and promising progression through clinical development. Its origins lie in Novo Nordisk’s long-standing leadership in metabolic disease research, building upon the success of GLP-1 receptor agonists.
n
- n
- Early Discovery & Preclinical Phase (Late 2000s – Early 2010s): Initial research focused on identifying novel peptides capable of modulating multiple metabolic pathways. The concept of a tri-agonist targeting GLP-1, GIP, and glucagon receptors emerged from an understanding of their synergistic roles in glucose homeostasis, energy expenditure, and appetite regulation. Preclinical studies demonstrated significant improvements in glycemic control, weight loss, and lipid profiles in various animal models, along with favorable effects on cardiac function.
- Phase I Development (2015-2017): The first-in-human studies for NV-345 commenced, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and patients with type 2 diabetes. These early trials established a favorable safety profile and demonstrated dose-dependent effects on glucose reduction and modest weight loss, validating the multi-agonist approach in humans.
- Phase II Program (2018-2021): A series of Phase II trials (e.g., ARTEMIS-IIa and ARTEMIS-IIb) explored different doses and durations of NV-345 in patients with type 2 diabetes, obesity, and non-alcoholic steatohepatitis (NASH). These studies consistently showed superior efficacy compared to GLP-1 mono-agonists in terms of HbA1c reduction and weight loss. Crucially, exploratory endpoints also hinted at positive effects on blood pressure, lipids, and markers of cardiovascular risk, providing the impetus for a large-scale cardiovascular outcomes trial. The results from the Phase II program, published in leading medical journals, generated considerable excitement within the scientific community and among investors.
- Initiation of Phase III ARTEMIS (2022): Based on the compelling Phase II data and the urgent unmet need for therapies that comprehensively address both metabolic and cardiovascular risks, Novo Nordisk initiated the Phase III ARTEMIS trial. The trial was designed as a randomized, double-blind, placebo-controlled study, with a primary endpoint of time to first occurrence of a 3-point MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke). The ambitious enrollment target of 18,500 patients underscored the company’s confidence and the scale of the potential impact.
- Enrollment Completion & Data Lock (2025): Patient recruitment for ARTEMIS was completed ahead of schedule in early 2025, a testament to the strong interest from investigators and patients. Following a rigorous data cleaning and validation process, the baseline data was locked for analysis in mid-2026, leading to the current presentation at AHA 2026.
- Ongoing Follow-up (2026-2028): Patients are currently in the active follow-up phase, with the trial projected to conclude in late 2028, followed by a rapid data analysis and presentation of the primary outcomes. The detailed baseline characteristics released today provide crucial context for interpreting these future results.
n
n
n
n
n
n
n
This meticulously planned and executed development timeline highlights the significant investment and scientific rigor behind NV-345, positioning it as a potential frontrunner in the next generation of cardiometabolic therapies.
Supporting Data: Deep Dive into the Patient Landscape and Analyst Expectations
The baseline data presented for the ARTEMIS trial provides a robust statistical snapshot of the patient population, reinforcing the trial’s relevance and potential impact. Beyond the demographic and clinical figures, this section delves into what these numbers signify for the trial’s power, generalizability, and the market’s anticipation.
Statistical Power and Trial Design:
The large sample size of 18,500 patients is critical for a cardiovascular outcomes trial (CVOT). Given the event rates typically observed in high-risk T2D and ASCVD populations, this number provides sufficient statistical power to detect a meaningful reduction in MACE with high confidence, even if the effect size is modest. The trial is designed with a non-inferiority margin, followed by superiority testing, which is standard for CVOTs evaluating new diabetes therapies. The high prevalence of established ASCVD (72%) ensures a sufficient number of cardiovascular events will occur during the follow-up period, making the trial efficient in demonstrating potential benefits.
Subgroup Analysis Potential:
The detailed baseline data will enable future subgroup analyses, which could be crucial for understanding differential treatment effects. For instance, analyzing outcomes based on baseline BMI, HbA1c levels, duration of diabetes, presence of heart failure, or chronic kidney disease could inform personalized treatment strategies if NV-345 proves effective. The global diversity of the cohort will also allow for exploration of ethnic and regional differences in response.
Analyst and Market Perspectives:
Following the baseline data presentation, industry analysts from leading financial institutions have reiterated their optimistic outlook on NV-345.
Dr. Eleanor Vance, Senior Pharmaceutical Analyst at Global Pharma Insights, commented, "The ARTEMIS baseline data paints a clear picture: Novo Nordisk has enrolled precisely the high-risk, complex patient population that stands to benefit most from a truly comprehensive cardiometabolic therapy. The high rates of established ASCVD, uncontrolled diabetes, and obesity confirm the significant unmet need and the potential market size for NV-345. This isn’t just a diabetes drug; it’s positioned as a cardiovascular risk reducer, which significantly expands its commercial potential."
Forecasts from various market intelligence firms suggest that if ARTEMIS demonstrates superiority in MACE reduction, NV-345 could achieve peak annual sales exceeding $15 billion globally, positioning it as a blockbuster drug. The market is particularly keen on multi-agonists due to their potential to offer broader benefits than single-target therapies, addressing the complex pathophysiology of cardiometabolic disease more holistically. The current market leaders, primarily GLP-1 receptor agonists, have already demonstrated significant CV benefits, and NV-345’s additional GIP and glucagon agonism is hypothesized to confer even greater metabolic and potentially cardiovascular advantages.
Furthermore, the high prevalence of obesity (78% with BMI ≥30 kg/m²) in the ARTEMIS cohort is noteworthy. While not the primary endpoint, any significant weight loss observed with NV-345 in this population could further bolster its clinical utility and market appeal, especially given the growing recognition of obesity as a disease itself and a major driver of cardiovascular risk.
Official Responses: Novo Nordisk’s Vision and Expert Endorsement
The presentation of the ARTEMIS baseline data was accompanied by statements from key figures at Novo Nordisk and leading experts, underscoring the significance of the trial and the potential impact of NV-345.
Dr. Martin Jensen, Executive Vice President and Head of Global Drug Development at Novo Nordisk, articulated the company’s strategic vision: "Today’s presentation of the ARTEMIS baseline data is a testament to the rigorous scientific foundation and meticulous execution behind NV-345. We have successfully enrolled a truly representative, high-risk population of patients with type 2 diabetes and established cardiovascular disease – individuals who urgently need more effective and comprehensive treatment options. The data confirms that ARTEMIS is well-positioned to provide definitive answers regarding NV-345’s potential to improve cardiovascular outcomes, building on our legacy in diabetes and obesity care. We are committed to advancing therapies that address the interconnected challenges of metabolic and cardiovascular health, and NV-345 represents a significant step forward in this endeavor."
Professor Anya Sharma, Principal Investigator for the ARTEMIS trial and Head of Cardiology at a prominent academic medical center, emphasized the clinical relevance of the trial’s design: "The ARTEMIS trial is addressing a critical unmet need. Patients with both advanced type 2 diabetes and established cardiovascular disease face a substantially increased risk of recurrent cardiovascular events and mortality. While existing therapies have made strides, there’s still a significant residual risk. The baseline characteristics of our enrolled patients clearly demonstrate that we are studying a population where even incremental improvements in cardiovascular outcomes could translate into profound benefits for patient quality of life and longevity. The multi-agonist mechanism of NV-345 offers a unique opportunity to target multiple pathophysiological pathways simultaneously, which is particularly exciting."
Independent experts also weighed in on the implications of the baseline data. Dr. David Chen, a leading endocrinologist and past president of a major diabetes association, commented, "The ARTEMIS trial’s baseline data provides confidence in its scientific integrity. The enrollment of such a high-risk cohort, with significant comorbidities and polypharmacy, makes any future positive results highly generalizable to real-world clinical practice. If NV-345 demonstrates a superior cardiovascular benefit, it will undoubtedly become a cornerstone therapy, offering a powerful new tool for clinicians battling these complex chronic diseases."
These statements collectively highlight the high expectations surrounding NV-345 and the ARTEMIS trial, reflecting both the scientific community’s hope for a new therapeutic breakthrough and Novo Nordisk’s strategic commitment to innovation in cardiometabolic health.
Implications: Reshaping Treatment Paradigms and Market Dynamics
The baseline data from the ARTEMIS trial, presented at AHA 2026, has far-reaching implications across the pharmaceutical industry, clinical practice, and public health. Should NV-345 prove successful in reducing cardiovascular events, its impact could be profound.
For Clinical Practice and Patients:
A positive outcome from ARTEMIS, demonstrating superior cardiovascular benefit, would likely establish NV-345 as a first-line or early-line therapy for patients with type 2 diabetes and established cardiovascular disease. Given its multi-agonist mechanism, it could potentially offer a more comprehensive approach than existing treatments by simultaneously improving glycemic control, promoting significant weight loss, and reducing cardiovascular risk. This could lead to:
- Improved Patient Outcomes: A reduction in MACE would translate directly into fewer heart attacks, strokes, and cardiovascular deaths, significantly improving patient prognosis and quality of life.
- Simplified Treatment Regimens: For patients on multiple medications, a single agent offering broad metabolic and cardiovascular benefits could simplify adherence and potentially reduce pill burden.
- New Therapeutic Avenues: NV-345’s success would validate the multi-agonist approach, spurring further research into similar compounds and potentially opening new frontiers in personalized medicine for cardiometabolic diseases.
For the Pharmaceutical Industry:
Novo Nordisk’s leadership in the GLP-1 space is well-established, and a successful ARTEMIS trial would cement its position as a dominant player in the broader cardiometabolic market.
- Market Leadership: NV-345 could become a significant revenue driver, potentially surpassing existing blockbusters and capturing a substantial share of the growing market for diabetes, obesity, and cardiovascular therapies.
- Competitive Landscape: The success of a tri-agonist would intensify competition among pharmaceutical companies. Rivals currently developing GLP-1/GIP co-agonists or other multi-targeted therapies would face increased pressure to demonstrate comparable or superior efficacy, potentially accelerating innovation.
- R&D Investment: A positive ARTEMIS result would likely encourage increased R&D investment in multi-receptor agonists and other novel mechanisms targeting complex chronic diseases. This could lead to a wave of new drug development in areas like NASH, heart failure with preserved ejection fraction (HFpEF), and even neurodegenerative diseases with metabolic links.
- Regulatory Precedent: The ARTEMIS trial’s robust design and large patient population could set a new standard for future cardiovascular outcomes trials, influencing regulatory expectations for novel therapies in this space.
For Public Health and Economic Burden:
The global burden of type 2 diabetes and cardiovascular disease is immense, straining healthcare systems worldwide. A highly effective therapy like NV-345 could have significant public health implications:
- Reduced Healthcare Costs: By preventing cardiovascular events, hospitalizations, and long-term complications, NV-345 could potentially lead to substantial cost savings for healthcare systems, despite its initial premium pricing.
- Improved Population Health: Widespread adoption of an effective therapy could contribute to a reduction in the overall incidence and prevalence of cardiovascular morbidity and mortality in high-risk populations, improving global health metrics.
- Policy and Guidelines: Positive trial results would undoubtedly influence clinical guidelines from major medical societies (e.g., AHA, ADA, ESC), recommending NV-345 as a standard of care. This would facilitate its integration into clinical pathways and expand access.
In conclusion, the baseline data from the ARTEMIS trial, presented at AHA 2026, has set a high bar for the future of cardiometabolic treatment. While efficacy data is still years away, the meticulous design and the high-risk, diverse patient cohort underscore the potential for NV-345 to emerge as a transformative therapy. The anticipation surrounding its eventual outcomes reflects a collective hope for a new era in the fight against the intertwined epidemics of diabetes, obesity, and cardiovascular disease, promising significant shifts in clinical practice, market dynamics, and ultimately, patient lives.
